Noul Co. Ltd.
Noul Co.,Ltd. engages in the in-vitro diagnosis and remote diagnosis business worldwide. It offers miLab, an AI-based blood diagnostic medical device that automates sample preparation, imaging, and analysis. The company also provides malaria diagnostics, blood cell morphology analysis, cancer morphology, immunohistochemistry services, and digital cervical cell analysis solution. Noul Co.,Ltd. was… Read more
Noul Co. Ltd. - Asset Resilience Ratio
Noul Co. Ltd. (376930) has an Asset Resilience Ratio of 27.49% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Noul Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Noul Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩8.01 Billion | 27.49% |
| Total Liquid Assets | ₩8.01 Billion | 27.49% |
Asset Resilience Insights
- Very High Liquidity: Noul Co. Ltd. maintains exceptional liquid asset reserves at 27.49% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Noul Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Noul Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Noul Co. Ltd. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Noul Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 55.37% | ₩20.93 Billion | ₩37.81 Billion | +20.08pp |
| 2023-12-31 | 35.29% | ₩19.61 Billion | ₩55.58 Billion | -5.16pp |
| 2022-12-31 | 40.45% | ₩10.46 Billion | ₩25.85 Billion | -10.63pp |
| 2021-12-31 | 51.08% | ₩10.20 Billion | ₩19.96 Billion | -4.01pp |
| 2020-12-31 | 55.10% | ₩8.57 Billion | ₩15.56 Billion | +2.68pp |
| 2019-12-31 | 52.41% | ₩1.46 Billion | ₩2.79 Billion | -- |